Welcome to our dedicated page for Tactile Systems SEC filings (Ticker: TCMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tactile Systems Technology, Inc. (Tactile Medical) SEC filings page for ticker TCMD provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed medical technology company incorporated in Delaware, Tactile Medical files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K under Commission File Number 001-37799.
Through these filings, investors can review detailed information on Tactile Medical’s business, including its focus on at-home therapies for lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. Periodic reports describe revenue from sales and rentals of the lymphedema product line and sales of the airway clearance product line, along with discussions of gross margin, operating expenses, net income or loss and non-GAAP measures such as Adjusted EBITDA as defined by the company.
Current reports on Form 8-K document material events, such as the release of quarterly financial results and the authorization of share repurchase programs for the company’s common stock. These filings may include information on the size and duration of repurchase authorizations and the company’s intention to fund them from cash and future cash flows.
On Stock Titan, TCMD filings are updated in near real time as they are posted to the SEC’s EDGAR system. AI-powered summaries highlight key points from lengthy documents, helping users quickly understand topics such as segment performance, capital allocation decisions and risk factor discussions without reading every page. Users can also review insider-related filings, including Forms 3, 4 and 5, to track equity transactions by directors and officers, and proxy statements on Schedule 14A for information on governance and executive compensation.
Whether you are analyzing Tactile Medical’s financial history, monitoring new 8-K disclosures or looking for details on its at-home therapy business, this page centralizes the company’s official SEC filings with concise AI-generated insights.
Tactile Systems Technology Chief Executive Officer Sheri Louise Dodd reported an open-market sale of 10,993 shares of common stock on February 24, 2026 at a weighted average price of
Tactile Systems Technology Inc. chief financial officer Elaine M. Birkemeyer reported an open-market sale of 7,701 shares of common stock on February 24, 2026. The shares were sold to cover taxes associated with the settlement of stock units.
The filing states a weighted average sale price of $28.9417 per share, with individual trades executed between $28.50 and $29.45 per share. After this transaction, Birkemeyer directly holds 134,819 shares of Tactile Systems common stock.
Tactile Systems Technology senior vice president Kristie Burns sold 6,246 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $28.9408 per share on February 24, 2026 to cover taxes associated with the settlement of stock units. After this sale, Burns directly owned 82,581 shares of Tactile Systems Technology common stock.
Kristie Burns reported proposed dispositions of common stock on a Form 144, listing multiple sale transactions with dates and share counts. The filing shows sales on 01/02/2026 of 5,139 shares for $148,260.15, on 02/23/2026 of 4,439 shares for $125,610.38, and on 02/24/2026 of 6,246 shares for $180,765.48. The document also lists a securities-to-be-sold entry showing 4,000 shares associated with Fidelity Brokerage Services LLC and a dollar figure of $113,880.00 with an action date of 02/25/2026.
Tactile Systems Technology chief financial officer Elaine M. Birkemeyer reported a mix of stock awards and related share sales. On February 20, 2026, she acquired 3,579, 6,765, and 15,575 shares of common stock through earned performance stock units tied to 2025 results, with some awards vesting immediately and others scheduled to vest in 2027 when 2026 performance is determined.
On February 23, 2026, she executed open‑market sales of 5,322 shares at a weighted average price of $28.2827 and 196 shares at a weighted average price of $28.6892, described as sales to cover taxes associated with stock‑unit settlement. Following these transactions, she directly owned 142,520 shares of common stock.
Tactile Systems Technology CEO Sheri Louise Dodd reported both stock awards and share sales. On February 20, 2026, she acquired 19,751 and 28,216 common shares at no cost through performance stock units tied to 2025 results, with one tranche vesting in 2026 and another scheduled to vest in 2027. On February 23, 2026, she sold a total of 15,240 common shares in open-market transactions at weighted average prices of $28.2826 and $28.6891 per share to cover taxes associated with stock unit settlement. After these transactions, she directly holds 254,878 common shares.
Tactile Systems Technology senior vice president Kristie Burns reported both equity awards and share sales in this Form 4. On February 20, 2026, she acquired a total of 14,671 shares of common stock through performance stock units earned for 2025, with 3,490 and 4,058 PSUs vesting immediately and 7,123 PSUs scheduled to vest in 2027 once 2026 performance is determined.
On February 23, 2026, she sold 4,279 shares at a weighted average price of
Sheri L. Dodd filed a Form 144 notice reporting proposed sales of Common Stock tied to restricted stock vesting. The filing lists a sale activity dated
TCMD filed a Form 144 notice to sell 7,701 shares of common stock tied to restricted stock vesting on
The excerpt shows 5,518 shares were sold during the prior three months for
TCMD reports an intended resale of 6,246 common shares in a Form 144 filing.
The filing shows the shares tied to a restricted stock vesting transaction dated